A study by MIT researchers demonstrates the potential of a non-invasive gamma treatment to mitigate “chemo brain,” a condition associated with cognitive impairments in cancer patients undergoing chemotherapy. Initially aimed to treat Alzheimer’s disease, this therapy uses light and sound at a 40-hertz frequency to stimulate brain waves. (Source: PharmaTimes)
A new stroke therapy that delivers electrical pulses to the brain via a portable device will be tested in a pioneering trial to improve arm recovery after stroke. Led by researchers from Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield, this trial aims to determine if transcutaneous vagus nerve stimulation can enhance hand and arm strength during rehabilitation therapy for stroke survivors. (Source: PharmaTimes)
Researchers funded by the NIH have developed a method to detect toxic Aβ oligomers in patients’ blood, showing potential for early detection of Alzheimer’s disease. Tested on nearly 400 human blood samples, this method offers a way to intervene before significant brain damage occurs, and could also be adapted to detect other neurodegenerative diseases like Parkinson’s. (Source: NIH)
The FDA has approved Rezdiffra (resmetirom) for the treatment of noncirrhotic non-alcoholic steatohepatitis (NASH), also known as fatty liver disease. This approval, under the FDA’s Accelerated Approval program, is based on Phase III data showing Rezdiffra’s efficacy in reducing fat accumulating in the liver. (Source: European Pharmaceutical Review)
Swedish researchers at Chalmers University of Technology developed an AI model, named Lymphoma Artificial Reader System (LARS), that detects lymphatic cancer with 90% accuracy. This deep learning system, trained on over 17,000 images from more than 5,000 patients, assists radiologists by analyzing images from positron emission tomography to identify visual signs of cancer. (Source: PharmaTimes)
